Huntington’s disease (HD) is an autosomal fatal genetic disease in which degeneration of
neuronal cells occurs in the central nervous system (CNS). Commonly used therapeutics are cludemonoamine
depletors, antipsychotics, antidepressants, and tranquilizers. However, these drugs cannot
prevent the psychotic, cognitive, and behavioral dysfunctions associated with HD. In addition to
this, their chronic use is limited by their long-term side effects. Herbal drugs offer a plausible alternative
to this and have shown substantial therapeutic effects against HD. Moreover, their safety
profile is better in terms of side effects. However, due to limited drug solubility and permeability to
reach the target site, herbal drugs have not been able to reach the stage of clinical exploration. In
recent years, the paradigm of research has been shifted towards the development of herbal drugs
based nanoformulations that can enhance their bioavailability and blood-brain barrier permeability.
The present review covers the pathophysiology of HD, available biomarkers, phytomedicines explored
against HD, ongoing clinical trials on herbal drugs exclusively for treating HD and their
nanocarriers, along with their potential neuroprotective effects.